Journal of Receptor, Ligand and Channel Research
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability
(6519) Total Article Views
Authors: Juruena MF, de Sena EP, de Oliveira IR
Published Date August 2011
Volume 2011:4 Pages 49 - 55
Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira3
1Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil; 2Department of Pharmacology, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil; 3Department of Neurosciences and Mental Health, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil
Abstract: The treatment of schizophrenia has advanced because the therapeutic efficacy, tolerability, and safety profiles of atypical antipsychotics seem to be superior to those of classical neuroleptics. Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology, which is dose-dependent. As could be predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is clearly associated with lower use of anti-parkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. Amisulpride is well tolerated in terms of anxiety and insomnia. Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Hyperprolactinemia rapidly reverses after amisulpride discontinuation. Amisulpride benefits patients with negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium-/long-term treatment, as demonstrated in studies of up to 12 months. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. In conclusion, amisulpride is an antipsychotic agent with proven efficacy and good tolerability.
Keywords: antipsychotic agents, amisulpride, adverse events, pharmacology
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Professor Mario Juruena
Readers of this article also read:
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Evolution of a domain conserved in microtubule-associated proteins of eukaryotes
- Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches for the treatment of coronary heart disease
- Is gene activity in plant cells affected by UMTS-irradiation? A whole genome approach
- Discrimination between biological interfaces and crystal-packing contacts